Immune checkpoint inhibitors (ICIs) targeting PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-L1 have been widely developed and have shown good efficacy in treating non-small cell lung cancer (NSCLC). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.